Go or no go? Oncology decisions ahead for the FDA
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
One victory for biopharma over the coronavirus in 2020
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Who will follow Curis’s clinical validation?
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
TG adds a multiple sclerosis string to its bow
Hot on the heels of a successful Ash meeting, TG Therapeutics shows that it might have a multiple sclerosis challenger to Ocrevus.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Ash 2020 preview – early winners and losers
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
TG pulls victory from the jaws of defeat
The Unity-CLL trial shows ublituximab plus umbralisib conferring an unexpected progression-free survival benefit.
